Topical creams are becoming part of the mix of pain treatment options as doctors look for alternatives to addictive opioids.
Learn how to effectively ignite workers' compensation recovery by addressing some of the biggest return-to-work obstacles, including mental health comorbidities, social factors, and delayed intervention. See how data-driven strategies lead to successful claims management and faster employee recovery.
Discover how bone growth stimulators are accelerating recovery in workers’ comp. Nicole Usher joins the Enlyte Envision podcast to discuss how BGS devices support healing in complex fractures and spinal surgeries.
The U.S. Food and Drug Administration (FDA) recently approved Journavx (suzetrigine), a novel non-opioid medication developed by Vertex Pharmaceuticals for the treatment of moderate to severe acute pain in adults. This approval, announced on January 30, 2025, marks a significant milestone in pain management, introducing the first new class of oral medication for acute pain in over two decades.
Industry expert Michael Cwynar of Enlyte discusses how to strike the right balance between AI innovation and professional expertise in today’s rapidly evolving tech landscape.
Enlyte's field case management provides empathetic, innovative support for injured employees, guiding recovery with tailored solutions. Discover how our comprehensive approach can enhance your workers' compensation outcomes.
As reported by the Bureau of Labor and Statistics (BLS) in January 2025 for December 2024, the United States consumer price index increased to 2.9% over the preceding 12 months which is 0.5% higher than reported in October 2024.